The epidemiology of invasive fungal infections is changing, with new populations at risk and
the emergence of resistance caused by the selective pressure from increased usage of …

Fosmanogepix is a first-in-class antifungal currently in Phase 2 clinical trials for the treatment
of invasive fungal infections caused by Candida, Aspergillus and rare molds. Fosmanogepix …

These updated AST‐IDCOP guidelines provide information on epidemiology, diagnosis, and
management of Aspergillus after organ transplantation. Aspergillus is the most common …

Candidiasis is an infection caused by fungi from a Candida species, most commonly
Candida albicans. C. albicans is an opportunistic fungal pathogen typically residing on …

Several new antifungals are currently in late-stage development, including those with novel
pharmacodynamics/mechanisms of action that represent new antifungal classes …

The emergence of new fungal pathogens makes the development of new antifungal drugs a
medical imperative that in recent years motivates the talents of numerous investigators …

The airborne fungus Aspergillus fumigatus poses a serious health threat to humans by
causing numerous invasive infections and a notable mortality in humans, especially in …

The incidence of COVID-19-associated candidiasis (CAC) is increasing, resulting in a grave
outcome among hospitalized patients with COVID-19. The most alarming condition is the …

Azole-resistant A. fumigatus is an emerging threat that hampers our ability to successfully
treat patients with aspergillosis. Certain geographic regions and patient populations appear …

Invasive pulmonary aspergillosis (IPA), invasive mucormycosis (IM), and invasive fusariosis
(IF) are associated with high mortality and morbidity. Fosmanogepix (FMGX) is a first-in …